Aurinia Pharmaceuticals announced that seven of the 10 patients with lupus nephritis (LN) enrolled in its AURION study, evaluating short-term predictors of clinical response to voclosporin treatment, achieved complete disease remission at 24 weeks. In addition, the company reported that patients who achieved remission at eight weeks continued in remission at 24 weeks.
The monoclonal antibody against interleukin (IL)-6, called PF-04236921, was found to be efficient at reducing severe flares in systemic lupus erythematosus (SLE) patients — particularly in those with high disease activity — when administered at a 10 mg dose. The study, “Efficacy and safety of an interleukin 6 monoclonal antibody for…
Researchers at Temple University Hospital are taking part in a large, global Phase 3 clinical trial to evaluate whether a novel, investigational drug for systemic lupus erythematosus (SLE) is more effective than previously approved medications. This trial (NCT02446912), one of several pivotal and ongoing studies of anifrolumab to treat moderately to severely active SLE,…
Aurinia Pharmaceuticals announced that its AURA-LV clinical trial, assessing voclosporin for the treatment of lupus nephritis (LN), has achieved its primary endpoint at its lower dose — complete disease remission at 24 weeks. Prespecified secondary endpoints at both dose levels were also reached in comparison to placebo, including partial remission as measured…
Consumption of foods rich in docosahexaenoic acid (DHA), an omega-3 fatty acid, can prevent the onset of systemic lupus erythematosus (SLE) and possibly other autoimmune diseases, according to a study published in the journal PLoS One. The study, by Melissa Bates from Michigan State University and colleagues, is titled “Silica-Triggered…
The very first time I stepped onto Californian soil, in 2013, I was instantly in love with the different culture, how I was completely immersed in something so foreign to everything I’d ever known. My wanderlust was born. From that day on, I’ve planned my life around my…
The University of Rochester Medical Center in New York will host a 10th Lupus Education Day on Saturday, Oct. 15, providing a forum for people with systemic lupus erythematosus (SLE) and their caregivers to interact and to better understand the latest developments in treating and managing the disease. “This is a great opportunity…
Large-scale analysis of genome-wide gene expression signatures allows researchers to discriminate between patients with active and inactive systemic lupus erythematosus — and could help physicians in adjusting treatment to control disease activity while minimizing the risk of side effects. The study reporting the method, “Clinical Application of a Modular…
The Lupus Research Alliance, together with the John and Marcia Goldman Foundation, funded a study that led to researchers identifying some 150 medications, approved by the U.S. Food and Drug Administration (FDA) for other diseases, that could be promising treatments for systemic lupus erythematosus (SLE). The study, published in the journal…
Patients with systemic lupus erythematosus (SLE) may be at increased risk of incident respiratory failure, according to a nationwide study by Taiwanese researchers. The study, “Effect of Systemic Lupus Erythematosus on the Risk of Incident Respiratory Failure: A National Cohort Study,” published in the journal PLoS One, also…